A phase 2 trial evaluated the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in patients with urothelial non-muscle invasive bladder cancer.

Chemohyperthermia Safe, Effective for NMIBC Adjuvant Treatment Patients who received BCG induction within 3 weeks or 3 weeks or more after surgery for nonmuscle-invasive bladder cancer did not differ ...

Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial ...

Urothelial carcinoma is the most common bladder cancer, with stage 1 indicating early-stage disease confined to the bladder lining. Diagnosis involves urinalysis, cystoscopy, TURBT, and imaging to ...

UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers Mar 05, 2026, 1:53 AM ET UroGen Pharma Ltd. (URGN) Stock Out of Ignorance 7.54K Followers ...

The benefit-risk profile was favorable, supporting UGN-102 mitomycin gel as a nonsurgical alternative to TURBT in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder ...

Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05). Background: To evaluate our 15-year long-term experience with patients treated with transurtehral resection ...

UGN-102 had similar disease-free survival outcomes in non-muscle-invasive bladder cancer, regardless of whether the therapy was given with surgery. Groups of patients with newly diagnosed and ...